SARMs for Research: What the Science Class Actually Is (and Isn't)

“SARM” is the most misunderstood three letters in the research-chemical market — simultaneously a legitimate pharmacological class and, as sold online, a byword for mislabeled bottles. This guide separates the class from the commerce.

The idea: biased agonism, decades early

SARMs were born in 1990s medicinal chemistry — the linolenic-acid-derived precursors at Allergan, then the propionamide and arylquinuclidine scaffolds — as an attempt to split the androgen signal: keep receptor activation in muscle and bone, reduce it in prostate and skin. Modern mechanistic work shows the “selectivity” is tissue-specific cofactor recruitment rather than clean on/off, which is exactly the interesting part for AR-signaling research (review with full pipeline table: Christiansen 2020).

Four properties define the class analytically: non-steroidal or 19-nor scaffolds, oral bioavailability without 17α-alkylation, no aromatase substrate behavior, and dose-dependent (not zero) suppression of the HPG axis in human trials — the enobosarm phase II data in older adults showed lean-mass gains alongside measurable testosterone suppression (PMC3177038).

The scaffold families in the catalog

Family	Prototype	Chemistry handle
Propionamide (S-4-type)	Andarine S-4	1,2-diaryl-5-aminoimidazole scaffold; visual-side-effect literature in trials
Arylpropionamide (QT/OSTX-type)	Ostarine, LGD-4033	The most-published SARM scaffold; enobosarm programs
Bicyclic aryl (GTX-type)	RAD-140	Design rationale and preclinical profile: Hwang 2013
Rev-erb agonist (adjacent class)	SR-9009	Not an AR ligand at all — circadian-clock pathway tool sold in SARM aisles
GH secretagogue (adjacent)	MK-677	Ghrelin-receptor mimetic; the Nass 2008 RCT is its clinical benchmark

Note the two “adjacent” rows: market categorization and pharmacology routinely disagree — a pattern worth internalizing before buying anything called a SARM.

Why this market has a reputation problem

Van Wagoner et al. ran GC-MS/MS on 76 products marketed online as SARMs (JAMA 2017): barely half matched their labels; the rest contained undisclosed pro-drugs, other active agents, or sub-therapeutic amounts — findings the authors tied directly to case reports of drug-induced liver injury. The LiverTox chapter is the sober summary: no SARM is approved anywhere, several have documented hepatotoxicity signals, and the supplement-channel products are analytically unreliable as a class. That paper is also the strongest argument for the batch-tested, CAS-documented catalog model: the research answer to a broken market is documentation.

What legitimate use looks like

Receptor and signaling research with published preclinical doses, doping-control method development, and reference-standard work — all of which need exactly what the gray market lacks: verified identity per batch. That’s the lane these compounds occupy here (quality process), and the reason every product page states the trial failures as plainly as the assay interest.

Not approved at any dose, by any route, for human use — and the WADA prohibited list treats all of them as banned substances in sport.

For laboratory research use only. Not medical advice.